Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for pain or severe dyspnea, or as an antitussive, either alone or compounded with paracetamol (acetaminophen) (as in co-dydramol) or aspirin.
Market Analysis and Insights: Global Dihydrocodeine Market
Due to the COVID-19 pandemic, the global Dihydrocodeine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Oral accounting for % of the Dihydrocodeine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Cough Suppressant segment is altered to an % CAGR throughout this forecast period.
China Dihydrocodeine market size is valued at US$ million in 2021, while the US and Europe Dihydrocodeine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Dihydrocodeine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Dihydrocodeine include AHPL, Teofarma, Mundipharma, Napp Pharmaceuticals, Aspen Pharmacare, Martindale-Hubbell, Duopharma Biotech Berhad, Wockhardt and Auden Mckenzie Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Dihydrocodeine Scope and Segment
Dihydrocodeine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Dihydrocodeine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral
Injection
Segment by Application
Cough Suppressant
Analgesic
By Company
AHPL
Teofarma
Mundipharma
Napp Pharmaceuticals
Aspen Pharmacare
Martindale-Hubbell
Duopharma Biotech Berhad
Wockhardt
Auden Mckenzie Pharma
WraSer
GlaxoSmithKline
G.L. Pharma
Daiichi Sankyo
Fuso Pharmaceutical
Nichi-Iko Pharmaceutical
Takata Pharmaceutical
Toyo Seikan Group
Teva
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE